Lenvima 4mg Capsule

About

Lenvima 4mg Capsule contains lenvatinib, a multi-kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3, fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4, platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT. By inhibiting these receptor tyrosine kinases, lenvatinib disrupts tumor angiogenesis, tumor growth, and other pro-oncogenic signaling pathways. This targeted therapy is crucial in managing various advanced cancers where these pathways are dysregulated. Its comprehensive inhibitory profile contributes to its efficacy in slowing disease progression and improving patient outcomes in specific malignancies.

Uses

• Treatment of differentiated thyroid cancer (DTC) refractory to radioactive iodine.
• Management of advanced renal cell carcinoma (RCC) in combination with everolimus.
• First-line treatment for unresectable hepatocellular carcinoma (HCC).
• Treatment of advanced endometrial carcinoma in combination with pembrolizumab.

Directions For Use

Take orally once daily with or without food, at approximately the same time each day. Swallow the capsule whole.

Benefits

• Targets multiple pro-angiogenic and oncogenic pathways.
• Effective in various advanced solid tumors.
• Can slow tumor growth and progression.
• Offers a treatment option for refractory cancers.
• Available in an oral capsule formulation.
• Improves progression-free survival in certain indications.

Side Effects

• Hypertension (high blood pressure)
• Fatigue and asthenia
• Diarrhea
• Decreased appetite
• Weight loss
• Nausea and vomiting
• Proteinuria (protein in urine)
• Hand-foot syndrome (palmar-plantar erythrodysesthesia)
• Hypothyroidism
• Headache
• Dysphonia (hoarseness)
• Abdominal pain

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it may exacerbate liver-related side effects or interact with the medication.
• Pregnancy - Contraindicated during pregnancy due to potential fetal harm. Women of childbearing potential must use effective contraception.
• Breastfeeding - Breastfeeding is not recommended during treatment and for at least one week after the last dose due to potential harm to the infant.
• Liver - Use with caution and dose adjustment may be required in patients with moderate to severe hepatic impairment.
• Kidney - Dose adjustment may be necessary for patients with severe renal impairment. Monitor renal function regularly.
• Lung - Monitor for signs of pulmonary embolism or interstitial lung disease, though these are rare.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.